Discontinued — last reported Q3 '24

Products & Services · Transactional price remaining performance obligation

Roche License Obligation — Transactional price remaining performance obligation

Alnylam Pharmaceuticals Roche License Obligation — Transactional price remaining performance obligation remained flat by 0.0% to $375.00M in Q3 2024 compared to the prior quarter.

Analysis

StatementSegment
First reportedQ1 2024
Last reportedQ3 2024
Rolls up toDeferred Revenue
Metric ID: alny_segment_roche_license_obligation_transactional_price_remaining_performance_obligation

Historical Data

3 periods
 Q1 '24Q2 '24Q3 '24
Value$375.00M$375.00M$375.00M
QoQ Change—+0.0%+0.0%
Range$375.00M – $375.00M
Current Streak2+ quarters growth

Frequently Asked Questions

What is Alnylam Pharmaceuticals's roche license obligation — transactional price remaining performance obligation?
Alnylam Pharmaceuticals (ALNY) reported roche license obligation — transactional price remaining performance obligation of $375.00M in Q3 2024.